This site is intended for health professionals only
Monday 27 May 2019
Share |

Topic: neurology

May 20, 2019
A team recently cataloged the neurological symptoms of patients who had received CAR T-cell therapy to better understand its neurotoxic side effects
The recent advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionised the clinical treatment of cancer. Under the umbrella of immunotherapy, CAR T-cell treatment trains and strengthens a patient's own immune system to attack tumors. Early successes in clinical trials have led to approval of the treatment for recurrent blood cancers, including leukaemia and lymphoma.
 
November 20, 2018
Galcanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide, which plays a role in migraine attacks, blocking its downstream function

Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorisation for Emgality® (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month.1

 

June 4, 2018
Tegsedi has been approved by the EMA for treatment of stage 1 and 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of its orphan drug Tegsedi™ (inotersen), for the treatment of Stage 1 or Stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR amyloidosis).1

 

 

June 1, 2018
Nanoparticles carrying two drugs can cross the blood-brain barrier and shrink glioblastoma tumors

Researchers have devised a new drug delivering nanoparticle that could provide a better way to treat glioblastoma.

 

The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumour cells. One drug damages tumour cells’ DNA, while the other interferes with the systems cells normally use to repair such damage.

 

In a study of mice, the researchers showed that the particles could shrink tumours and prevent them from growing back.

 

May 24, 2018
European programme to help people access edaravone for ALS treatment established by pharmaceutical companies

Global pharmaceutical organisations have joined forces to improve access to a treatment for amyotrophic lateral sclerosis (ALS).

 

Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) in Europe to initiate a ‘Managed Access Program’ for Edaravone, an intravenous treatment for ALS. The initiative is also known as ‘Early Access Program’.

 

Edaravone has been approved for use as a treatment for ALS in Japan, South Korea and the USA.

 

May 17, 2018
NICE U-turn recommends Biogen’s Avonex® (interferon beta-1a) for relapsing-remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has recommended global biotechnology  company Biogen’s Avonex® (interferon beta-1a) as an option for treating relapsing-remitting multiple sclerosis.

 

May 11, 2018
Neuromuscular blocking agents have a well-documented history of causing catastrophic injuries or death when inadvertently administered to adult and paediatric patients who were not receiving proper ventilatory assistance

Because neuromuscular blockers paralyse the muscles necessary for breathing, some patients have died or sustained serious, permanent injuries if the paralysis was not witnessed by a practitioner who could intervene.

 

April 27, 2018
<p>Valproate must no longer be prescribed to women or girls of childbearing potential unless they are on the pregnancy prevention programme (PPP)</p>

The Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate to protect public health.

 

Valproate medicines (Epilim, Depakote and generic brands) must no longer be prescribed to women or girls of childbearing potential unless they are on the pregnancy prevention programme (PPP) the regulator announced this month [April 24]. Valproate is a treatment for epilepsy and bipolar disorder.

 

April 19, 2018
<p>Novartis announces Aimovig&trade; could be an effective preventive treatment option for episodic migraine patients where previous treatments have failed</p>

A treatment for patients with episodic migraines could at least halve the number of days they experience them every month, researchers have found.

 

This April, healthcare organisation Novartis announced the results of a study that looked specifically at episodic migraine patients who had previously failed 2 to 4 preventive treatments, due to lack of efficacy and/or intolerable side effects.

 

March 19, 2018
International consensus document on arrhythmias and cognitive function has been published

Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online in EP Europace,1 a European Society of Cardiology journal, and presented at EHRA 2018.2

 

February 25, 2018
Because Parkinson's disease can affect nerve function outside of the brain, the research team hypothesised that any change in nerve function may be seen in the protein levels in tears

Tears may hold clues to whether someone has Parkinson's disease, according to a preliminary study that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, 21-27 April 2018.

 

February 16, 2018
Nusinersen demonstrated stabilisation or improvement from baseline in motor function in individuals with 5q spinal muscular atrophy where the natural history of the disease is a decline in motor function over time

Biogen and Ionis Pharmaceuticals, Inc have announced end of study results from CHERISH, the Phase III study evaluating Spinraza® (nusinersen) for the treatment of individuals with later-onset 5q spinal muscular atrophy (SMA), were published in The New England Journal of Medicine.

 

The full manuscript titled, “Nusinersen Versus Sham Control in Later-Onset Spinal Muscular Atrophy,” appears in the 15 February 2018 issue of The New England Journal of Medicine.

 

February 9, 2018
Pharmacists have a vital role in early identification and reconciliation of medications in PD patients and this has the potential to prevent deterioration and prevent further morbidity in this patient profile.

Abstract

Introduction Parkinson's disease (PD) is a high-risk chronic condition putting patients at risk of a number of potential complications if not managed appropriately. Emergency departments (EDs) are often ill-equipped to reconcile and continue vital medications for PD, and dramatic deterioration in symptoms and increased morbidity may occur as a result. The role of pharmacists in early reconciliation in this high-risk patient group is not fully explored in the current literature. 

 

February 1, 2018
The study showed that eslicarbazepine acetate monotherapy was non-inferior to twice-daily controlled-release carbamazepine, the current standard of care

Bial and Eisai have announced that leading clinical journal, Epilepsia, has published positive results from a pivotal Phase III monotherapy study of once-daily Zebinix® (eslicarbazepine acetate) in newly diagnosed focal epilepsy patients.1
 

January 23, 2018
The trial met its primary endpoint of percentage of patients on erenumab (AMG 334) achieving at least a 50% reduction of migraine days versus placebo, and all secondary endpoints

Novartis has announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

 

January 19, 2018
Managed access agreement to be developed in parallel to urgently provide effective new treatment to patients in England

The National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit Spinraza (nusinersen), the first and only disease-modifying treatment for 5q spinal muscular atrophy (SMA), for assessment via the Single Technology Appraisal (STA) route.

 

January 12, 2018
If licensed, ocrelizumab will be the first and only treatment option for adults in the European Union with primary progressive multiple sclerosis

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

 

December 13, 2017
Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, USA

Bial and Eisai have announced new real-world audit data presented at the American Epilepsy Society (AES) Annual Meeting 2017, which add to the existing clinical trials examining the effectiveness and tolerability of Zebinix® (eslicarbazepine acetate).

 

November 30, 2017
Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use

Novartis has announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase III STRIVE study evaluating erenumab in the prevention of episodic migraine (defined in STRIVE as 4 to 14 migraine days per month).1

 

November 10, 2017
If licensed, ocrelizumab will be an important new treatment option for adults with active relapsing forms of multiple sclerosis, approved on the basis of superior efficacy on three major markers of disease activity and disability progression compared to comparative control groups

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

 

November 9, 2017
NICE also recommends use of Merck’s multiple sclerosis therapy cladribine (Mavenclad®) for highly active disease in adults

NHS England has entered into a commercial agreement that allows NHS patients in England immediate access to the innovative new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad®).1

 

NHS England and Merck, the manufacturer of cladribine tablets, have partnered on the commercial access agreement, representing an example of a “win-win-win” for the NHS, patients and industry at a time of intense financial pressure on the NHS.

October 5, 2017
Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone® 40mg.

Synthon has announced that it has successfully concluded the decentralised procedures for glatiramer acetate 40mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe.

 

Synthon received regulatory clearance in all 27 EU/EEA member states involved in the procedures. Granting of national marketing authorizations will follow in the near future.
 

September 22, 2017
The NHS price for a single 10mg in 1mL prefilled syringe is £45.76

Special Products Ltd is pleased to announce that Epistatus® 10 mg Oromucosal Solution, Midazolam, is now available to prescribe. 
 

July 13, 2017
Report finds three quarters of UK MS specialists surveyed agree one in four people with MS surveyed were not even aware that treatments could help delay the onset of disability

Sanofi and its specialty care global business unit, Sanofi Genzyme, has published a report - The Missing Pieces, showing that the majority (74%) of UK multiple sclerosis (MS) healthcare professionals who completed a survey believe that people with MS face delays in starting on disease modifying treatments (DMTs).1

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine